Try our beta test site
Trial record 1 of 1 for:    Bigfoot
Previous Study | Return to List | Next Study

Bigfoot Biomedical Clinical Research Center (CRC) Trial

This study has been completed.
Sponsor:
Collaborators:
Jaeb Center for Health Research
Profil Institute for Clinical Research, Inc.
Information provided by (Responsible Party):
Bigfoot Biomedical Inc.
ClinicalTrials.gov Identifier:
NCT02849288
First received: July 20, 2016
Last updated: December 16, 2016
Last verified: December 2016
  Purpose
The trial is designed to assess safety and feasibility of the Bigfoot Biomedical Type 1 Diabetes Management System (T1DMS) in up to 50 participants in a closely monitored Clinical Research Center (CRC) environment.

Condition Intervention Phase
Type 1 Diabetes Mellitus
Device: Bigfoot Biomedical Type 1 Diabetes Management System (T1DMS)
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Bigfoot Biomedical Clinical Research Center (CRC) Trial

Resource links provided by NLM:


Further study details as provided by Bigfoot Biomedical Inc.:

Primary Outcome Measures:
  • Evaluate performance of the algorithm/ system commanded delivery of insulin in response to glucose trends from the CGM. in an effort to avoid hypoglycemia and hyperglycemia. [ Time Frame: Data will be evaluated upon completion of an individual participant (data collected over approximately 48 hours of use), upon completion of each age cohort, and upon completion of the trial ]
    Annotated graphs will be used to assess this outcome.

  • Assessment of safety outcomes and serious adverse events and device related adverse effects. [ Time Frame: Data will be evaluated upon completion of an individual participant (data collected over approximately 48 hours of use), upon completion of each age cohort, and upon completion of the trial ]

Secondary Outcome Measures:
  • Measures of glycemic control [ Time Frame: Data will be evaluated upon completion of an individual participant (data collected over approximately 48 hours of use), upon completion of each age cohort, and upon completion of the trial ]
    Additional measures include but are not limited to, mean glucose (arithmetic and geometric), Glucose variability as assessed by coefficient of variation and standard deviation (arithmetic and geometric). Percentage of time spent below or above glucose threshold levels.

  • System functionality as evidenced by the availability of CGM data [ Time Frame: Data will be evaluated upon completion of an individual participant (data collected over approximately 48 hours of use), upon completion of each age cohort, and upon completion of the trial ]
    Includes but is not limited to the percentage of time CGM values were available for individual participants and for all participants pooled.


Enrollment: 20
Study Start Date: July 2016
Study Completion Date: December 2016
Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intervention
Use of the Investigational Bigfoot Type 1 Diabetes Management System (T1DMS)
Device: Bigfoot Biomedical Type 1 Diabetes Management System (T1DMS)
Automated Insulin Delivery System
Other Name: T1DMS

  Eligibility

Ages Eligible for Study:   7 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Insulin dependent type 1 diabetes (T1D) for at least one year
  2. Age ≥ 7 years of age
  3. Weight ≥ 26 kg
  4. HbA1c <10%
  5. Total BASAL insulin dose (24 hour cumulative total) that is ≥ 5 units and ≤ 72 units per day
  6. Insulin regimen stable on either multiple daily insulin injections (MDI) or insulin infusion pump therapy for ≥ 6 months. Regimen must include basal insulin and the use of a rapid acting analog insulin to cover meals (e.g., Novolog, Humalog or Apidra)

    • For participants on MDI, basal insulin must be either once daily Lantus (Glargine) or once daily Levemir (Detemir). The once daily basal insulin dose must be administered in the evening or at bedtime
  7. Able to engage in at least 60 minutes of moderate exercise if ≥ 12 years of age (e.g., walking or biking) and if ≥ 7 and < 12 years of age moderate activity (e.g., walking or active play)
  8. Willing and able to refrain from use of any medication containing acetaminophen during participation in the study (from the time of consent until study exit)
  9. Willing and able to use Humalog insulin during the CRC admission
  10. Able to speak and read English

Exclusion Criteria:

  1. Females who are sexually active and able to conceive will be excluded if they are not currently using or agree to continue use for the duration of the study an effective method of contraception as determined by investigator
  2. Females who are pregnant or intending to become pregnant during participation in the trial

    • Females who are capable of childbearing must have a negative pregnancy test at the time of the screening visit and the pregnancy test must be repeated at enrollment if it was done > 14 days prior

  3. Presence of any condition that in the opinion of the investigator impairs the participant's ability to use the system (e.g.,visual impairment that interferes with ability to read the display)
  4. Unable or unwilling to use study devices and follow study procedures including the meal and exercise/ activity challenges in the CRC.
  5. A current condition that would prevent the use of a study devices, including blood glucose meter (BGM), continuous glucose monitoring (CGM) or insulin pump (CSII)
  6. Current participation within the last 60 days in another clinical research study that involves an intervention

    • Participation in research studies involving data collection only is not an exclusion (e.g.,T1D Exchange Registry)

  7. Anticoagulant therapy other than aspirin
  8. Severe hypoglycemia resulting in seizure OR loss of consciousness within 30 days prior to enrollment
  9. Diabetic ketoacidosis (DKA) requiring treatment in a healthcare facility within 30 days prior to enrollment
  10. Current use (defined as within the last 3 months) of any medication intended to lower glucose other than insulin (e.g., use of Metformin, Liraglutide, would be exclusions)
  11. Current use (defined as within the last 3 months) of any medication that according to the dose, frequency, and route of administration may result in hyperglycemia in the investigator's judgment (e.g., current use of oral steroids)

    • Regular use of inhaled or intranasal steroids is permitted

  12. Presence of significant renal disease as evidenced by the presence of any of the following:

    • Current dialysis therapy
    • Serum creatinine of ≥ 2.0 mg/dL within 30 days of enrollment

    For screening purposes, serum creatinine levels will be tested in participants who meet any of the following criteria:

    • A≥10 year history of T1D
    • Are ≥ 45 years of age
  13. Presence or history of clinically significant cardiovascular disease (e.g., myocardial infarction, pacemaker, acute coronary syndrome, therapeutic coronary intervention, coronary bypass or stenting procedure, atrial or ventricular fibrillation, treatment for arrhythmia, stable or unstable angina, episode of chest pain of cardiac etiology with associated ECG changes or positive stress test/ cardiac catheterization, congestive heart failure, or cerebrovascular event)
  14. ECG findings that indicate participation in the planned exercise/ activity session would be contraindicated as determined by trained personnel at the respective clinical center(s)

    • For screening purposes, ECGs must be completed within 30 days of enrollment in participants who meet any of the following criteria:

    • A ≥ 10 year history of T1D and ≥ 20 years of age
    • Are ≥ 45 years of age
  15. History of adrenal insufficiency
  16. A diagnosis of gastroparesis or impaired gastric motility that required pharmacological or surgical treatment
  17. Celiac Disease (CD) diagnosed < 12 months ago or CD that is currently inadequately treated as determined by the investigator
  18. Current alcohol abuse or eating disorder as determined by the investigator
  19. Use or abuse of controlled substances without a prescription in the 6 months prior to enrollment
  20. History of hemoglobinopathy, sickle cell disease, or blood dyscrasia; blood transfusion within 3 months of enrollment
  21. Hematocrit that is above or below the normal reference range of the lab used within 14 days of enrollment
  22. Presence or history of any medical or psychiatric condition, or the use of any medication or therapy, that in the opinion of the investigator may be a contraindication to participation in the study
  23. Unstable hypertension, thyroid disease, or depression as evidenced by an adjustment in therapy for the condition within the last 2 months, or as determined by investigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02849288

Locations
United States, California
William Sansum Diabetes Research Institute
Santa Barbara, California, United States, 93111
Stanford University
Stanford, California, United States, 94305
United States, Colorado
Barbara Davis Center for Childhood Diabetes
Aurora, Colorado, United States, 80045
Sponsors and Collaborators
Bigfoot Biomedical Inc.
Jaeb Center for Health Research
Profil Institute for Clinical Research, Inc.
  More Information

Responsible Party: Bigfoot Biomedical Inc.
ClinicalTrials.gov Identifier: NCT02849288     History of Changes
Other Study ID Numbers: TST-10025
Study First Received: July 20, 2016
Last Updated: December 16, 2016
Individual Participant Data  
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on March 22, 2017